Sage Therapeutics, Inc.
NASDAQ: SAGE0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Barry E. Greene
- Employees
- 353
- Headquarters
- Cambridge, United States
- IPO year
- 2014
- Market cap
- $544.9M
- Website
- https://www.sagerx.com
Loading SAGE…
Loading profile data…Frequently asked questions about SAGE
What does Sage Therapeutics, Inc. (SAGE) do?
Sage Therapeutics, Inc. functions as a biopharmaceutical enterprise, dedicated to the discovery, development, and market introduction of therapeutic agents aimed at central nervous system (CNS) conditions. Its primary medication is ZULRESSO, an intravenous form of brexanolone, prescribed for the treatment of postpartum depression (PPD) in adult...
Where does SAGE trade?
Sage Therapeutics, Inc. (SAGE) trades on the NASDAQ Global Market.
What sector is SAGE in?
Sage Therapeutics, Inc. (SAGE) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Sage Therapeutics, Inc.?
Barry E. Greene is the chief executive officer of Sage Therapeutics, Inc. (SAGE).
Where is Sage Therapeutics, Inc. headquartered?
Sage Therapeutics, Inc. is headquartered in United States.
Does SAGE pay a dividend?
Sage Therapeutics, Inc. (SAGE) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did SAGE go public?
Sage Therapeutics, Inc. (SAGE) completed its initial public offering in 2014.